BRAF and neoplasm: For patients with BRAF V600E RAIR DTC, treatment options for first-line treatment would lie between the multikinase TKIs Lenvatinib or Sorafenib, versus targeted therapy with Dabrafenib and Trametinib based on the FDA tumor agnostic approval.